IOBT Company Profile and Key Details

IOBT has shown mixed momentum, gaining 1.9% over the past week and -21.31% over the past quarter, though year-to-date performance is down -15.32%. Short-term trend indicators are bullishly aligned (SMA20 6.52%, SMA50 -23.87%, SMA200 -67.03%). The stock’s 14-day RSI is 46.2 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.13% below its high and over 74.87% above its low. Average 10-day trading volume of 19.28 million shares is significantly above the 3-month average of 12.31 million, indicating heightened recent market interest.

IO Biotech, Inc. generated EPS of -$1.34 over the past year. Five-year average earnings growth is -25.33%. Wall Street analysts project EPS growth of 39.99% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.21. Next year's EPS is expected at $18.52. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $0.50. The high target offers 13233.33% upside. The low target suggests 1566.67% downside. The mean target is $2.50. This offers 8233.33% upside. IO Biotech, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -9.68%. The prior quarter beat by -59.63%. Over the last six quarters, Apple has recorded several small beats. These include 24.14% in November 12, 2024.

IO Biotech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.88. This means the shares are trading below this model’s fair value.

IO Biotech, Inc. (NASDAQ:IOBT) closed at $0.03 USD, losing -$0.01 (-26.09%) from the previous close of $0.04. The stock is currently mid-range between its 52-week high and low $0.03 and $2.79. With a market capitalization of about $2.32 million, IO Biotech, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.44). Key stats such as the average daily volume over the past year has been around 12.30 million shares, trading with heavier-than-usual volume. Headquartered in Copenhagen, None, IO Biotech, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mai-Britt Zocca, the company employs approximately 80 people and listed since November 05, 2021. IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform.

IO Biotech, Inc. has 65.88 million shares outstanding. The public float is 31.28 million shares, elevated short interest at 2.69% of float. This equals 851.15 thousand shares. The short ratio is 1.64 days. Institutional investors hold 64.07% of the float. Insiders own 0.36%. Lundbeckfond Invest A/S holds 6.05 million shares, Novo Holdings A/S has 4.35 million shares and Vivo Capital IX, LLC has 3.16 million shares.

IO Biotech, Inc. trades at a P/E ratio of -0.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.37 suggesting the stock is closer to book value. The P/FCF stands at -0.03, also above market averages.

Our AI price prediction model suggests that IO Biotech, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by April 16, 2026, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -69.04%, reaching $0.01 by July 01, 2026, with a range of $0.00 to $0.07. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 02, 2027, within a range of $0.00 to $0.05.

IO Biotech, Inc. (NASDAQ:IOBT) shares are down -15.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows IO Biotech, Inc. trading at a premium to the broader market with a P/E of -0.02. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $8.42, suggesting 25968.11% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-69.04% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.